John, I did find this story, but it doesn't answer the big question, did they have sufficient data to present a finding, and was the finding positive for EECP and VASO.
Anyway, here's the most recent news story:
WESTBURY, N.Y.--(BW HealthWire)--March 25, 1997--Vasomedical Inc. (NASDAQ: VASO), manufacturer and marketer of EECP(R) - a noninvasive treatment for patients suffering with angina pectoris--has received a new patent from the U.S. Patent Office encompassing multiple operating features for its EECP(R) equipment. These features will be incorporated in the future Model MC3. "The issuance of this patent helps protect important technology advances that will permit broader therapeutic application of EECP(R) therapy expanding our market opportunities", noted Anthony Viscusi, president and CEO of Vasomedical. Viscusi went on to say, "The patent covers features that will facilitate treatment of diverse patient groups as well as provide an integrated ability to monitor the patients' physical signs while undergoing treatment. We will vigorously enforce our patent rights and be vigilant about possible infringement." The new patent extends until the year 2013. Patent applications are pending in overseas markets. Vasomedical is a medical technology company devoted to the development, manufacture and commercialization of innovative and cost-effective cardiovascular products and processes.
CONTACT: Vasomedical Inc.
Natalie Karp, 516/997-4600 ext. 776
By the way, they could have had a great finding which would have gone totally unnoticed with the recent turmoil in the market. Hope so....
Mark |
